Clinical Trials for Medical Products in India

clinical trials in IndiaIndia’s large population offers many opportunities for medical device, pharmaceutical, and biotechnology companies looking to conduct clinical trials overseas. However, managing a smooth clinical trial process in India’s growing markets and evolving regulatory environment can be a challenging task.

Pacific Bridge Medical has strong expertise in the Indian clinical trial landscape and offers comprehensive clinical trial consulting services. Our on-the-ground personnel are trained regulatory professionals who can assist you in managing your clinical trials in India to completion successfully and efficiently, either as your contract research organization (CRO) or by overseeing and auditing your Indian CRO.

For more details regarding clinical trials in India and the associated regulatory requirements, please click on the following questions.

Clinical Trials for Medical Devices in India

Are local clinical trials required for product registration?

In India, medical device approval generally does not require local clinical studies, since foreign data can often be used. Clinical trials in India are typically only required for risky medical devices without predicates.

What are the requirements for conducting clinical trials?

For new medical devices, local clinical trials in India involve completing Application Form 44, receiving approval from the ethics committee, following protocol and Good Clinical Practices (GCP), and reporting all adverse events. All medical device clinical trials need to be registered in the Clinical Trial Registry of India (CTRI) and will be reviewed by the Medical Device Advisory Committee, which is part of the CDSCO.

Clinical Trials for Pharmaceuticals in India

Are local clinical trials required for product registration?

In order to register pharmaceuticals in India, clinical trial data must be provided. Foreign clinical trial data is generally accepted, as long as the foreign clinical trial inspection certifies the data complies with Good Clinical Practices (GCP) and the Code of Federal Regulations (CFR).

Rather than conduct a full clinical trial in India, some companies may do an Indian bioequivalence (BE) study instead. The BE study must follow BE and Bioavailability (BA) study guidelines (2005), and the Checklist for Pre-screening Applications (2014). In about 50% of the cases, foreign companies can apply to waive the BE study. Waivers are typically granted based on Finished Pharmaceutical Product (FPP) formulation and marketing status. If a branded drug was approved in India four or more years ago, the bioequivalent drug may be approved without any local studies in India.

What are the requirements to obtain approval for clinical trial initiation?

The DCGI mandates that all drug clinical trials must be registered with the Clinical Trial Registry of India (CTRI) before the trial begins. Clinical trial registration involves identifying relevant authorities and appropriate patients. Prior to CTRI approval, companies must register with the appropriate Independent Ethics Committees (IEC) and Institutional Review Boards (IRB), submit a dossier to the DCGI, and receive approval from the three-tier review system. Multinational trials that include India must be registered both internationally and in the CTRI. The DCGI announced that Phase III studies done overseas must include at least one Indian participant. The CDSCO accepts multinational studies that involve Indian patients.

What are the requirements for conducting clinical trials?

Throughout pharmaceutical clinical trials in India, the status of the trial and other key issues must be updated publicly. Review and approval time for all clinical trial applications is about 6 months.

Contact us today for a consultation with our India experts regarding conducting clinical trials in India for your product.

Related Resources

Visit our Resource Center to view free webcasts and charts or read publications, news, and research reports on the Asia medical markets.

Related Blog Posts

Visit our Blog for more insight into key trends and regulations from the Asia medical markets, written by our leading consultants and researchers.